Pfizer has entered into a manufacturing agreement with Vivet Therapeutics, a Paris-based gene-therapy company developing treatments for inherited liver disorders, under which Pfizer will provide clinical supply for a Phase I/II clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare liver disorder. The trial is expected to commence in early 2021. Further terms of the agreement were not disclosed.

In March 2019, the companies announced a collaboration under which Pfizer acquired a minority equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. The companies also announced that they would collaborate on the development of VTX-801, for which an investigational new drug (IND) application is planned to be filed with the US Food and Drug Administration in 2020. Under that deal, Pfizer paid approximately EUR 45 million ($53 million) upon signing of the collaboration and may pay up to EUR 560 million ($654 million) inclusive of the option-exercise payment and subject to certain clinical, regulatory, and commercial milestones.

The Phase I/II clinical supply for VTX-801 will be manufactured in Pfizer’s facility in Chapel Hill, North Carolina.

Source: Vivet Therapeutics